The Claim
In obese Chinese adults, 12 weeks of liraglutide monotherapy at 1.8 mg/day is associated with a 6.6% reduction in body weight and significant decreases in visceral and subcutaneous abdominal fat, but these changes are not significantly correlated with improvements in fasting glucose or HbA1c.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese Chinese adults, taking liraglutide at 1.8 mg per day for 12 weeks leads to a 6.6% loss in body weight and reduced abdominal fat, but these changes do not correspond to changes in fasting glucose or HbA1c levels.
See the scientific wording
In obese Chinese adults, 12 weeks of liraglutide monotherapy at 1.8 mg/day is associated with a 6.6% reduction in body weight and significant decreases in visceral and subcutaneous abdominal fat, but these changes are not significantly correlated with improvements in fasting glucose or HbA1c, suggesting glucose metabolism benefits may occur independently of overall fat loss.
Liraglutide lowers fat buildup in the liver, which removes a block that stops insulin from working properly in liver cells. This allows the liver to stop making too much glucose, bringing blood sugar levels down without needing to lose overall body fat.
What the research says
1 studyLiraglutide helped obese Chinese adults lose weight and belly fat, and also improved their blood sugar. But the study found that the blood sugar improvement was more linked to less fat in the liver, not just less overall fat — meaning the drug helps blood sugar in ways beyond just making people thinner.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.